CO-ALEPH-OBJECTS-INC
20.12.2018 09:02:09 CET | Business Wire | Press release
Aleph Objects, Inc., is organizing for growth as 3D printing technology and its market segments continue to expand. The company, manufacturer of the reliable, award-winning LulzBot® 3D Printers , announced new roles for two executive team members this week.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181220005175/en/
Grant Flaharty, Aleph Objects, Inc. President, is stepping into the role of CEO in addition to his existing role. With over 20 years of executive experience, Flaharty is uniquely qualified to lead Aleph Objects through this evolving and increasingly demanding market in additive manufacturing technology. “The changes we are incorporating will drive significant growth as we rapidly expand our products, our reseller network, and our social presence into global markets. We are anticipating a record-breaking year with a larger percentage of business being received from outside the US,” Flaharty said. “The response rate for LulzBot’s high quality workhorse 3D printers is setting the bar for growth going forward.”
Steven Abadie, who has been with Aleph Objects since its launch in 2011, will be leveraging his expertise in 3D printing technology in his new position as CTO. His primary focus will be on driving the company’s development efforts in terms of new and innovative products. “We are working towards significant leaps in technology and design across our product line,” Abadie said. “In 2019, we expect to make a strong statement with new product offerings, all with a continued focus on Free Software, Libre Innovation, and Open Source Hardware.”
Aleph Objects’ user base has evolved to encompass enterprise and professional markets, and the trend is expected to continue as the technology becomes more sophisticated and accessible. “Additive manufacturing technology just keeps expanding at a mind-blowing rate,” said Jeff Moe, Aleph Objects, Inc. Founder. “The internal re-alignment of the company will ultimately serve to maintain a stronger focus on new product introduction going into this period of massive growth.”
https://www.youtube.com/watch?v=EAMr3jjEqUs
About Aleph Objects, Inc.
Aleph Objects, Inc. is the Colorado-based designer and manufacturer of the award-winning line of LulzBot® 3D Printers for rapid prototyping, additive manufacturing, educators, and hobbyists. Aleph Object’s core company values of Free Software, Libre Innovation, and Open Source Hardware enable users to uniquely modify both software and hardware to bring their imagination into reality. For more information, visit LulzBot.com /.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181220005175/en/
./ContentItem/Format ./ContentItem/MimeType ./ContentItem/Characteristics/Property LulzBot Platform of 3D Printers and Tool Heads 13555 169848 57326534 12246 4683Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom